Armata Pharmaceuticals (ARMP) CEO awarded 421,226 stock options at $11.61

Rhea-AI Filing Summary

Armata Pharmaceuticals, Inc. reported that Chief Executive Officer Deborah Birx received a grant of stock options for 421,226 shares of common stock on March 9, 2026. The options carry an exercise price of 11.6100 per share and fully represent her derivative holdings after this grant.

According to the terms, 25% of the options vest on March 9 of each of 2027, 2028, 2029, and 2030, in each case conditioned on her continuous service through the relevant vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Birx Deborah

(Last) (First) (Middle)

5005 MCCONNELL AVENUE

(Street)

LOS ANGELES CA 90066

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Armata Pharmaceuticals, Inc. [ ARMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$11.61	03/09/2026		A		421,226		(1)	03/09/2036	Common Stock	421,226	$0.00	421,226	D

Explanation of Responses:

1. Twenty-five percent (25%) of the Stock Options shall vest on March 9th of each of 2027, 2028, 2029, and 2030, in each case subject to continuous service through the applicable vesting date.

	/s/ Deborah Birx	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Armata Pharmaceuticals (ARMP) disclose in this Form 4 for Deborah Birx?

Armata Pharmaceuticals disclosed that CEO Deborah Birx received a grant of stock options covering 421,226 shares of common stock at an exercise price of $11.61 per share. This is classified as a grant or award acquisition, not an open-market purchase or sale.

How many stock options did the Armata (ARMP) CEO receive and at what exercise price?

Deborah Birx received stock options for 421,226 underlying shares of Armata Pharmaceuticals common stock. The options have an exercise price of $11.61 per share, meaning she can buy shares at that price once the options vest and are exercised, subject to the grant terms.

What is the vesting schedule for Deborah Birx’s Armata (ARMP) stock options?

The stock options vest in four equal annual installments. Twenty‑five percent of the grant vests on March 9 in each of 2027, 2028, 2029, and 2030, and each vesting tranche requires Deborah Birx to remain in continuous service through the applicable vesting date.

Are the Armata (ARMP) stock options granted to Deborah Birx an open-market transaction?

No, the transaction is reported with code A, meaning a grant, award or other acquisition of derivative securities. It reflects compensation in the form of stock options, not an open-market purchase or sale of Armata Pharmaceuticals common stock by the CEO.

How many Armata (ARMP) stock options does Deborah Birx hold after this grant?

After this transaction, Deborah Birx is reported as holding 421,226 stock options directly. These options each relate to one share of Armata Pharmaceuticals common stock, giving her the right to acquire shares at $11.61 per share if and when they vest and are exercised.